New Zealand vaccine producer closer to goal by integrating mRNA Covid-19 technology with Australian research partner
COVID-19 Vaccination Corporation (CVC), New Zealand’s most experienced group of vaccine researchers have joined forces
with Australia’s BASE Nucleic Acids Biomanufacturing Facility to produce an mRNA COVID-19 vaccine.
To date, CVC has been working on its own unique T-cell COVID-19 vaccine to complement existing vaccines as an enhancer.
CVC’s vaccine is designed to work differently to currently marketed COVID-19 vaccines, with the main aim of protecting
against COVID’s current and future variants, including the more infectious Delta variant, which has resulted in a strict
nationwide level 4 lockdown in New Zealand.
“CVC’s vaccine can do this because it does not rely on generating antibodies, unlike all COVID-19 vaccines being
administered at the moment,” says CVC Chief Executive Dr Robert Feldman.
Since launching its vaccine research efforts in 2020, two events have spurred CVC into expanding its programme to
include the development of a new mRNA vaccine. Firstly, CVC now has successful pre-clinical results which are
significant for progressing its research.
Secondly, the well-documented efficacy of mRNA-based vaccines from Moderna and Pfizer/BioNTech have encouraged
researchers, with the promise of this additional approach broadening the applicability of CVC’s technology to multiple
delivery platforms.
“CVC’s vaccine is designed to protect not only against existing variants but also ones that may emerge in the future
which is a main focus. Our vaccine can be delivered using a variety of methods,” says Dr Feldman.
“Up until now, we have used a polypeptide subunit approach but, excitingly, we are now in a position to use the newer
mRNA method. We are particularly pleased to be able to collaborate with BASE to aid us in achieving our new goal,” he
adds.
As mRNA vaccines have demonstrated their abilities to be quickly developed, CVC’s collaboration with BASE Nucleic Acids
Biomanufacturing facility, part of the Protein Expression Facility at the University of Queensland, will explore how
CVC’s T-cell vaccine technology can be rapidly adapted to this emerging technology.
BASE is collaborating with CVC to design T-cell COVID-19 mRNA vaccine candidates. BASE will produce the mRNA vaccine’s
active substance which will be supplied to CVC for formulation and evaluation in pre-clinical studies.
“We are pleased to help accelerate CVC’s research effort to adapt its proprietary T-cell vaccine to the mRNA platform
technology and diversify the strategy employed to deliver the innovative vaccine,” says Dr Romain Tropée, Nucleic Acids
Production Lead at BASE Nucleic Acids Biomanufacturing Facility.
BASE is supported by Therapeutic Innovation Australia and the University of Queensland, offering advanced
biomanufacturing of high-quality and high-purity mRNA and DNA products to accelerate and enhance research translation.